Florence Joly

Summary

Country: France

Publications

  1. ncbi request reprint Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer
    F Joly
    Medical Oncology Department, Centre de Lutte contre le Cancer Francois Baclesse, Route de Lion sur Mer, BP 5026, 14076 Caen Cedex 05, France
    Int J Gynecol Cancer 16:77-82. 2006
  2. doi request reprint [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]
    Stéphanie Lheureux
    CLCC François Baclesse, Service de Recherche Clinique, Caen, France
    Bull Cancer 99:875-80. 2012
  3. doi request reprint French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3
    F Joly
    Departement d Oncologie Medicale, Unite de recherche clinique, Centre Francois Baclesse, Caen, France
    Support Care Cancer 20:3297-305. 2012
  4. ncbi request reprint High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
    F Joly
    Centre Francois Baclesse, Caen, F 14076, France
    Gynecol Oncol 78:361-8. 2000
  5. doi request reprint [Quality of life after radiotherapy for prostate cancer]
    F Joly
    Service d Oncologie Medicale, CLCC François Baclesse, 3 avenue du Général Harris, 14076 Caen Cedex, France
    Cancer Radiother 14:519-25. 2010
  6. doi request reprint Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
    Florence Joly
    Centre Francois Baclesse, Medical Oncology Department, Caen, France
    Gynecol Oncol 122:226-32. 2011
  7. doi request reprint Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial
    Florence Joly
    Centre Francois Baclesse, 3 avenue du Général Harris, Caen Cedex 05, France
    Gynecol Oncol 116:312-6. 2010
  8. doi request reprint Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study
    F Joly
    Centre Francois Baclesse, Avenue du General Harris, 14076 Caen Cedex 5, France
    Gynecol Oncol 115:382-8. 2009
  9. doi request reprint [Evidence based of chemoradiotherapy in cervix carcinoma]
    F Joly-Lobbedez
    CHU de la Côte de Nacre, 14033 Caen cedex 9, France
    Cancer Radiother 13:503-6. 2009
  10. doi request reprint Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study
    Florence Joly
    Departement d Oncologie Medicale, Centre François, Baclesse, France
    Clin Genitourin Cancer 7:E28-33. 2009

Detail Information

Publications28

  1. ncbi request reprint Efficacy and tolerability of the ifosfamide-epirubicin combination in relapsed ovarian cancer
    F Joly
    Medical Oncology Department, Centre de Lutte contre le Cancer Francois Baclesse, Route de Lion sur Mer, BP 5026, 14076 Caen Cedex 05, France
    Int J Gynecol Cancer 16:77-82. 2006
    ..The combination of ifosfamide with newer anthracycline agents such as liposomal doxorubicin may be an alternative and needs further evaluation for use after first-line taxane-based chemotherapy...
  2. doi request reprint [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer]
    Stéphanie Lheureux
    CLCC François Baclesse, Service de Recherche Clinique, Caen, France
    Bull Cancer 99:875-80. 2012
    ..Studies are on going in first line indication (compared to docetaxel) and associated to other new hormone therapies...
  3. doi request reprint French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) version 3
    F Joly
    Departement d Oncologie Medicale, Unite de recherche clinique, Centre Francois Baclesse, Caen, France
    Support Care Cancer 20:3297-305. 2012
    ..The purpose of our study was to conduct linguistic validation of the French version of the FACT-Cog...
  4. ncbi request reprint High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
    F Joly
    Centre Francois Baclesse, Caen, F 14076, France
    Gynecol Oncol 78:361-8. 2000
    ..The aim of this study was to evaluate the impact of platinum dose intensity on pathological response rate and overall survival in patients with advanced ovarian adenocarcinoma...
  5. doi request reprint [Quality of life after radiotherapy for prostate cancer]
    F Joly
    Service d Oncologie Medicale, CLCC François Baclesse, 3 avenue du Général Harris, 14076 Caen Cedex, France
    Cancer Radiother 14:519-25. 2010
    ....
  6. doi request reprint Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial
    Florence Joly
    Centre Francois Baclesse, Medical Oncology Department, Caen, France
    Gynecol Oncol 122:226-32. 2011
    ....
  7. doi request reprint Association of pegylated liposomal doxorubicin and ifosfamide in early recurrent ovarian cancer patients: a multicenter phase II trial
    Florence Joly
    Centre Francois Baclesse, 3 avenue du Général Harris, Caen Cedex 05, France
    Gynecol Oncol 116:312-6. 2010
    ..To evaluate the efficacy of pegylated liposomal doxorubicin (PLD) and continuous infusion ifosfamide (IFO) in ovarian cancer patients who relapse within 1 year after first-line paclitaxel-platinum-based chemotherapy...
  8. doi request reprint Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study
    F Joly
    Centre Francois Baclesse, Avenue du General Harris, 14076 Caen Cedex 5, France
    Gynecol Oncol 115:382-8. 2009
    ..The aim of this phase II study was to assess the benefits of a weekly administration of topotecan and gemcitabine in patients with ovarian carcinoma having relapsed after platinum/taxane-based first-line chemotherapy...
  9. doi request reprint [Evidence based of chemoradiotherapy in cervix carcinoma]
    F Joly-Lobbedez
    CHU de la Côte de Nacre, 14033 Caen cedex 9, France
    Cancer Radiother 13:503-6. 2009
    ..New strategies combining new chemotherapy protocols or targeted therapy with radiation are promising but have to be evaluated in comparative clinical trials before use in routine...
  10. doi request reprint Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study
    Florence Joly
    Departement d Oncologie Medicale, Centre François, Baclesse, France
    Clin Genitourin Cancer 7:E28-33. 2009
    ..There is no standard second-line chemotherapy for patients who relapse with advanced urothelial carcinoma. A GETUG phase II clinical trial was designed to evaluate the response rate and the palliative clinical benefit of weekly paclitaxel...
  11. doi request reprint [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?]
    Florence Joly
    Departement d Oncologie Medicale, Centre Francois Baclesse, Caen Cedex, France
    Bull Cancer 98:1071-81. 2011
    ..In this purpose, studies in oncology on the reliability of simple tools based on patient reporting and adapted to clinical practice, as well as interventional studies on fatigue management are needed...
  12. ncbi request reprint Quality of life in long-term survivors of testicular cancer: a population-based case-control study
    F Joly
    Groupe Régional d Etudes sur le Cancer EA 1772, Centre Francois Baclesse, University of Caen Basse, NORMANDIE, 14076 Caen Cedex 5, France
    J Clin Oncol 20:73-80. 2002
    ..To evaluate quality of life and social problems in long-term survivors of testicular cancer...
  13. ncbi request reprint [Prognostic factors of localised, locally advanced or metastatic prostate cancer]
    Florence Joly
    Centre Francois Baclesse, 3, Avenue Général Harris, 14076 Caen Cedex
    Bull Cancer 94:F35-43. 2007
    ..Nowadays, the progress and accessibility to novel technologies applied to biology will make possible in the near future the assessment of new prognostic profiles based on genetic and/or proteomic tumour characteristics...
  14. doi request reprint Cognitive dysfunction and cancer: which consequences in terms of disease management?
    Florence Joly
    Department of Medical Oncology, Centre Francois Baclesse, Caen, France
    Psychooncology 20:1251-8. 2011
    ..The aim of this review is to stress the importance of cognitive dysfunction in cancer survivors, and to discuss the way of assessing and managing these troubles in clinical practice...
  15. doi request reprint Complete remission with tyrosine kinase inhibitors in renal cell carcinoma
    Laurence Albiges
    Medical Oncology Department, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    J Clin Oncol 30:482-7. 2012
    ..It remains a matter of debate whether therapy should be continued after CR...
  16. doi request reprint Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial
    Stéphanie Lheureux
    Medical Oncology Department, Clinical Research Department, Centre Francois Baclesse, 3 Avenue Général Harris, 14076 Caen Cedex 5, France
    Int J Gynecol Cancer 22:1483-8. 2012
    ..The aim of this multicenter study was to assess the efficacy of the combination topotecan-lapatinib in epithelial ovarian cancer relapsing after a first line of chemotherapy...
  17. doi request reprint One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer
    Sabine Noal
    Medical Oncology Department, Centre Francois Baclesse, Caen, France
    Int J Radiat Oncol Biol Phys 81:795-803. 2011
    ..The aim of this longitudinal study was to compare the impact of RT alone with that occurring after previous CT on quality of life...
  18. doi request reprint Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study
    Jean Christophe Eymard
    Institut Jean Godinot, Medical Oncology Department, Reims, France
    BJU Int 106:974-8. 2010
    ..To investigate the potential benefit of reintroducing docetaxel chemotherapy in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) who had initially responded to first-line docetaxel-based regimen...
  19. doi request reprint Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
    Patricia Pautier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Gynecol Oncol 116:157-62. 2010
    ..This phase II investigated efficacy and tolerability of gefitinib in combination with paclitaxel (P) and carboplatin (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal adenocarcinoma...
  20. doi request reprint Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data
    Katharina Gunzer
    Centre Francois Baclesse, Avenue du General Harris, 14076 Caen Cedex 5, France
    Expert Opin Biol Ther 10:615-30. 2010
    ..Although the main indications are nowadays defined in academic guidelines, some changes in traditional G-CSF use are being induced by the emergence of new chemotherapy schedules and new drugs...
  21. doi request reprint Evaluation of current practice: management of chemotherapy-related toxicities
    Stéphanie Lheureux
    Department of Clinical Research, Pitie Salpetriere Hospital, Paris, France
    Anticancer Drugs 22:919-25. 2011
    ..Albumin, creatinine clearance and lymphocyte should be routinely monitored at baseline to manage CT and to prevent their toxicities...
  22. ncbi request reprint Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma
    Alexandre Labiche
    Groupe Régional d Etudes sur le Cancer GRECAN EA 1772, IFR 146 ICORE, Universite de Caen Basse Normandie, Centre Francois Baclesse, Caen, France
    Histol Histopathol 24:425-35. 2009
    ..Since ovarian tumours have a particular progression and dissemination behaviour, vascularisation outside hot spots may also contribute to their evolution...
  23. doi request reprint Autobiographical memory, self, and stress-related psychiatric disorders: which implications in cancer patients?
    Bénédicte Giffard
    INSERM, U1077, Caen, France
    Neuropsychol Rev 23:157-68. 2013
    ..Recommendations for future research that will enhance understanding of the factors that contribute to autobiographical memory in cancer are suggested...
  24. doi request reprint [Endometrial cancer: place for adjuvant chemotherapy]
    Stéphane Lheureux
    CLCC François Baclesse, Service de Recherche Clinique, Caen, France
    Bull Cancer 99:85-91. 2012
    ..The indication of adjuvant chemotherapy must be discussed in this situation taking into account the patient's profile with potential comorbidities and risk of toxicities...
  25. doi request reprint [Clinical practice guidelines 2008 for the surgical treatment, medical first-line and consolidation treatments of patients with epithelial ovarian cancer--update. According to the methodology of Standards, Options: Recommendations (SOR)]
    Catherine Lhomme
    Institut Gustave Roussy, 94805 Villejuif, France
    Bull Cancer 95:881-6. 2008
    ..Following the monitoring process, we identified new data conferring sufficient elements to justify an updating of the CPG concerning the surgical, the medical fi rst-line and consolidation treatments of epithelial ovarian cancers...
  26. doi request reprint Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer
    Catherine Lhomme
    Institut Gustave Roussy, Service de Gynecologie, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France
    J Clin Oncol 26:2674-82. 2008
    ..To compare the safety and efficacy of carboplatin and paclitaxel administered with or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with advanced ovarian or primary peritoneal cancer...
  27. ncbi request reprint Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients
    Hugues Bourgeois
    Medical Oncology Unit, CHU de Poitiers, Poitiers, France
    Am J Clin Oncol 29:399-404. 2006
    ....
  28. ncbi request reprint Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer
    Hugues Bourgeois
    CHU de Poitiers, Poitiers, France
    Am J Clin Oncol 29:267-75. 2006
    ..This phase I-II trial aimed to determine the dose limiting toxicity (DLT) and recommended dose (RD) of a first-line combination of PLD and weekly paclitaxel...